The Annals of Applied Statistics

Bayesian data augmentation dose finding with continual reassessment method and delayed toxicity

Suyu Liu, Guosheng Yin, and Ying Yuan

Full-text: Open access

Abstract

A major practical impediment when implementing adaptive dose-finding designs is that the toxicity outcome used by the decision rules may not be observed shortly after the initiation of the treatment. To address this issue, we propose the data augmentation continual reassessment method (DA-CRM) for dose finding. By naturally treating the unobserved toxicities as missing data, we show that such missing data are nonignorable in the sense that the missingness depends on the unobserved outcomes. The Bayesian data augmentation approach is used to sample both the missing data and model parameters from their posterior full conditional distributions. We evaluate the performance of the DA-CRM through extensive simulation studies and also compare it with other existing methods. The results show that the proposed design satisfactorily resolves the issues related to late-onset toxicities and possesses desirable operating characteristics: treating patients more safely and also selecting the maximum tolerated dose with a higher probability. The new DA-CRM is illustrated with two phase I cancer clinical trials.

Article information

Source
Ann. Appl. Stat., Volume 7, Number 4 (2013), 2138-2156.

Dates
First available in Project Euclid: 23 December 2013

Permanent link to this document
https://projecteuclid.org/euclid.aoas/1387823313

Digital Object Identifier
doi:10.1214/13-AOAS661

Mathematical Reviews number (MathSciNet)
MR3161716

Zentralblatt MATH identifier
1283.62053

Keywords
Bayesian adaptive design late-onset toxicity nonignorable missing data phase I clinical trial

Citation

Liu, Suyu; Yin, Guosheng; Yuan, Ying. Bayesian data augmentation dose finding with continual reassessment method and delayed toxicity. Ann. Appl. Stat. 7 (2013), no. 4, 2138--2156. doi:10.1214/13-AOAS661. https://projecteuclid.org/euclid.aoas/1387823313


Export citation

References

  • Braun, T. M. (2006). Generalizing the TITE–CRM to adapt for early- and late-onset toxicities. Stat. Med. 25 2071–2083.
  • Cheung, Y. K. and Chappell, R. (2000). Sequential designs for phase I clinical trials with late-onset toxicities. Biometrics 56 1177–1182.
  • Coia, L. R., Myerson, R. and Tepper, J. E. (1995). Late effects of radiation therapy on the gastrointestinal tract. International Journal of Radiation Oncology, Biology, Physics 31 1213–1236.
  • Daimon, T., Zohar, S. and O’Quigley, J. (2011). Posterior maximization and averaging for Bayesian working model choice in the continual reassessment method. Stat. Med. 30 1563–1573.
  • Daniels, M. J. and Hogan, J. W. (2008). Missing Data in Longitudinal Studies: Strategies for Bayesian Modeling and Sensitivity Analysis. Monographs on Statistics and Applied Probability 109. Chapman & Hall/CRC, Boca Raton, FL.
  • Desai, S. P., Ben-Josef, E., Normolle, D. P., Francis, I. R., Greenson, J. K., Simeone, D. M., Chang, A. E., Colletti, L. M., Lawrence, T. S. and Zalupski, M. M. (2007). Phase I study of oxaliplatin, full-dose gemcitabine, and concurrent radiation therapy in pancreatic cancer. J. Clin. Oncol. 25 4587–4592.
  • Garrett-Mayer, E. (2006). The continual reassessment method for dose-finding studies: A tutorial. Clin. Trials 3 57–71.
  • Goodman, S. N., Zahurak, M. L. and Piantadosi, S. (1995). Some practical improvements in the continual reassessment method for phase I studies. Stat. Med. 14 1149–1161.
  • Heyd, J. M. and Carlin, P. B. (1999). Adaptive design improvements in the continual reassessment method for phase I studies. Stat. Med. 18 1307–1321.
  • Iasonos, A. and O’Quigley, J. (2011). Continual reassessment and related designs in dose-finding studies. Stat. Med. 30 2057–2061.
  • Lee, S. M. and Cheung, Y. K. (2011). Calibration of prior variance in the Bayesian continual reassessment method. Stat. Med. 30 2081–2089.
  • Leung, D. H. Y. and Wang, Y. G. (2002). An extension of the continual reassessment method using decision theory. Stat. Med. 21 51–63.
  • Little, R. J. A. and Rubin, D. B. (2002). Statistical Analysis with Missing Data, 2nd ed. Wiley, Hoboken, NJ.
  • Liu, S., Yin, G. and Yuan, Y. (2013). Supplement to “Bayesian data augmentation dose finding with continual reassessment method and delayed toxicity.” DOI:10.1214/13-AOAS661SUPP.
  • Mauguen, A., Le Deley, M. C. and Zohar, S. (2011). Dose-finding approach for dose escalation with overdose control considering incomplete observations. Stat. Med. 30 1584–1594.
  • Möller, S. (1995). An extension of the continual reassessment methods using a preliminary up-and-down design in a dose finding study in cancer patients, in order to investigate a greater range of doses. Stat. Med. 14 911–922.
  • Muler, J. H., McGinn, C. J., Normolle, D., Lawrence, T., Brown, D., Hejna, G. and Zalupski, M. M. (2004). Phase I trial using a time-to-event continual reassessment strategy for dose escalation of cisplatin combined with gemcitabine and radiation therapy in pancreatic cancer. J. Clin. Oncol. 22 238–243.
  • O’Quigley, J. and Paoletti, X. (2003). Continual reassessment method for ordered groups. Biometrics 59 430–440.
  • O’Quigley, J., Pepe, M. and Fisher, L. (1990). Continual reassessment method: A practical design for phase 1 clinical trials in cancer. Biometrics 46 33–48.
  • Postel-Vinay, S., Gomez-Roca, C., Molife, L. R., Anghan, B., Levy, A., Judson, I., Bono, J. D., Soria, J., Kaye, S. and Paoletti, X. (2011). Phase I trials of molecularly targeted agents: Should we pay more attention to late toxicities? J. Clin. Oncol. 29 1728–1735.
  • Shen, L. Z. and O’Quigley, J. (1996). Consistency of continual reassessment method under model misspecification. Biometrika 83 395–405.
  • Tanner, M. A. and Wong, W. H. (1987). The calculation of posterior distributions by data augmentation. J. Amer. Statist. Assoc. 82 528–550.
  • Wages, N. A., Conaway, M. R. and O’Quigley, J. (2011). Continual reassessment method for partial ordering. Biometrics 67 1555–1563.
  • Wages, N. A., Conaway, M. R. and O’Quigley, J. (2013). Using the time-to-event continual reassessment method in the presence of partial orders. Stat. Med. 32 131–141.
  • Yin, G. and Yuan, Y. (2009). Bayesian model averaging continual reassessment method in phase I clinical trials. J. Amer. Statist. Assoc. 104 954–968.
  • Yuan, Y. and Yin, G. (2011). Robust EM continual reassessment method in oncology dose finding. J. Amer. Statist. Assoc. 104 818–831.

Supplemental materials